Analyse the Effect of Semaglutide on Vascular Structure and Function in Patients With Early Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 107 participants.

Also called NCT05303857

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 107 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05303857
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Germany (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05303857. Randomized; triple masking; primary purpose treatment. Start 2022-03-03 (actual); primary completion 2023-12-15 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Analyse the Effect of Semaglutide on Vascular Structure and Function in Patients With Early Type 2 Diabetes
Acronym
SEMA
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Semaglutide Pen Injector
Intervention (Drug)
Placebo
Lead sponsor
University of Erlangen-Nürnberg Medical School (class: other)

Record details

Record id
cardio:ct-nct05303857
Content hash
d511ca0b89b0c39460a08e71b116edf2acaf26a266ea0894df671f6606a00ba8